je.st
news
MSD Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin
2013-07-26 16:16:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck Sharpe and Dohme (MSD), known as Merck in the United States and Canada, issued the following statement regarding the conclusion of the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) review of GLP-1, or incretin-based, therapies, including sitagliptin. Language: English Contact: MSDMedia:Pam Eisele, +1-908-423-5042Michael Close, +1-267-305-1211Investor:Carol Ferguson, +1-908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: type
including
review
statement
Category:Biotechnology and Pharmaceuticals